Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Just not for me
Paratuberculosis Lytic phages with extensive host range across rapid- and slow-growing pathogenic mycobacterial species
Oxygen consumption did not discriminate between those that developed DGF and those that functioned immediately (Supplementary Information, Fig
Pureza 99% HPLC, identidad por MS y COA por lote
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
US$ 24.82
US$ 29.06
US$ 22.89